<DOC>
	<DOC>NCT00798369</DOC>
	<brief_summary>This 8-week study is designed to determine the target dose of canakinumab (ACZ885) for the management of acute flare in gout patients who are contraindicated to Non-Steroidal anti-inflammatory drugs and/or colchicine. The efficacy of ACZ885 will be compared to the corticosteroid triamcinolone acetonide.</brief_summary>
	<brief_title>Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>History of at least 1 gout flare prior to the Screening Visit Meeting the American College of Rheumatology (ACR) 1977 preliminary criteria for the classification of acute arthritis of primary gout. Presence of acute gout flare for no longer than 5 days. Baseline pain intensity &gt; or = to 50 mm on the 0100 mm VAS. Contraindicated for, intolerant or unresponsive to NSAIDs, colchicine or both. Rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis. Presence of severe renal function impairment Contraindication to intramuscular injection Known presence or suspicion of active or recurrent bacterial, fungal or viral infection at the time of enrollment Evidence of active pulmonary disease Live vaccinations within 3 months prior to the start of the study Use of forbidden therapy Other protocoldefined inclusion/exclusion criteria applied</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Acute flares</keyword>
	<keyword>Gout</keyword>
	<keyword>Anti-interleukin-1Î² monoclonal antibody</keyword>
	<keyword>Colchicine</keyword>
	<keyword>Triamcinolone acetonide</keyword>
</DOC>